Sanofi’s BTK in­hibitor rilz­abru­ti­nib helped 23% of adults with a rare au­toim­mune blood dis­or­der achieve tar­get platelet counts in a Phase 3 tri­al, com­pared to … ...

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings Rilzabrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a protein that ...

Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant ...

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China ...